Involvement of tumor necrosis factor-α in the upregulation of CXCR4 expression in gastric cancer induced by Helicobacter pylori by Zhao, Chenghai et al.
RESEARCH ARTICLE Open Access
Involvement of tumor necrosis factor-a in the
upregulation of CXCR4 expression in gastric








Background: H. pylori, whose infection increases tumor invasiveness and metastasis, is generally labelled as the
strongest risk factor for the development of gastric cancer. It appears not to be a coincidence that there is also an
overexpression of CXCR4 and an obvious involvement in gastric cancer metastasis. The aim of this study attempts
to investigate and further to establish a link between them. With H. pylori being a potent inducer of TNF-a,
whether TNF-a, a tumor promoter, is involved in the induction of CXCR4 expression by H. pylori was also under
research in this study.
Methods: Expression of CXCR4, TNF-a, IL-6 and IL-1b mRNA was determined by real-time PCR. CXCR4 protein
expression was detected by Western blotting. Concentrations of TNF-a, IL-6 and IL-1b in cell culture supernatants
were measured using the Quantikine Elisa kit. To abrogate TNF-a expression in HGC27 cells, TNF-a RNAi plasmid
was used to transfect them.
Results: Levels of CXCR4 and TNF-a mRNA were significantly higher in H. pylori-positive gastric cancers (n = 19)
compared to H. pylori-negative ones (n = 15). A subsequently Spearman’s rank correlation test showed there was a
positive correlation between the level of CXCR4 mRNA and that of TNF-a in 34 primary gastric cancers. Other
results followed: Expression of CXCR4 and TNF-a was upregulated in gastric cancer cell MKN45 and HGC27 after
infection with H. pylori 26695 (cag PAI
+ ) or Tx30a (cag PAI
- ); The induction of CXCR4 expression by H. pylori was
inhibited significantly by a neutralizing TNF-a antibody, infliximab; CXCR4 expression was upregulated in MKN45
cells after treatment with exogenous TNF-a or co-culture with macrophage, and was downregulated in HGC27
cells after transfection with TNF-a RNAi plasmid. There was a significant increase in the migration of MKN45 cells
treated with H. pylori 26695, and a strong inhibition when AMD 3100, a CXCR4 antagonist, or infliximab, was
added.
Conclusions: Our findings demonstrated that H. pylori upregulates CXCR4 expression in gastric cancer through
TNF-a.
Background
It is well accepted that Helicobacter pylori (H. pylori) is
a strong risk factor for the development of various gas-
tric diseases, namely chronic gastritis, peptic ulcers, gas-
tric mucosa-associated lymphoid tissue lymphoma and
gastric cancer, and it is acknowledged that the interac-
tion between H. pylori and epithelial cells contributes to
such development. In fact, H. pylori infection induces
inflammation in microenvironment of the stomach asso-
ciated with induction of proinflammatory cytokines,
such as tumor necrosis factor-a (TNF-a), interleukin-1b
(IL-1b) and IL-6[1-3], which makes gastric carcinogen-
esis conducive.
H. pylori infection also increases tumor invasiveness
and metastasis [4-6], though the mechanism is still not
well understood. The process of cancer metastasis is not
random, and different cancers have their preferred hom-
ing sites. Just like leukocyte trafficking, tumor cell
migration is critically regulated by chemokine/chemo-
kine receptor system. Another focus of our attention is
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overexpressed in a series of cancers (gastric cancer
included) by far [7,8]. Studies have indicated CXCL12/
CXCR4 axis is involved in gastric cancer metastasis [9].
Therefore it arouses great interests to find a link
between H. pylori infection and CXCR4 overexpression
in gastric cancer.
One of the key chemical mediators implicated in
inflammation-associated cancers is TNF-a,a n dt h e r ei s
now substantial evidence in its involvement in promo-
tion and progression of experimental and human can-
cers [10,11]. True to its name, high doses of regional
TNF-a can lead to hemorrhagic necrosis via selective
destruction of tumor blood vessels. However, it can
unexpectedly act as an endogenous tumor promoter
when produced in the tumor microenvironment. Our
interest is consequently drawn to its involvement in the
induction of CXCR4 expression by H. pylori, a potent
inducer of TNF-a, which is known to upregulate a ser-
ies of cytokines, chemokines, adhesion molecules and
growth factors in cancers.
Methods
Gastric cancer cell lines and tissue specimens
The human gastric cancer cell MKN45 and HGC27
were obtained from Keygen Biotech. Co. (Nanjing,
China), and were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum, at 37°C in a humid incuba-
tor with 5% CO2. 34 primary gastric cancer specimens
were acquired from patients under operation with all
their informed consent at Shengjing hospital, Chinese
Medical University, and were frozen in liquid nitrogen
immediately after surgical removal. Haematoxylin- and
eosin-staining sections were prepared for assessment of
the percentage of tumor cells, and only specimens with
> 70% tumor cells were selected for analysis. This study
was carried out with the approval of the ethical commit-
tee of China Medical University. All experiments were
done at least three times.
Macrophage cell line RAW264.7
The macrophage cell RAW 264.7 was provided by the
American Type Culture Collection (Rockville, MD,
USA), and was maintained in Dulbecco’sm o d i f i e d
Eagle’s medium, supplemented with 10% fetal bovine
serum, at 37°C in a humid incubator with 5% CO2.
H. pylori strains
H. pylori strain 26695 (ATCC 700392, cag PAI
+ )a n d
Tx30a (ATCC 51932, cag PAI
- ) were offered by ATCC
(Rockville, MD, USA). They were grown on sheep blood
agar plates at 37°C under microaerophilic conditions.
Bacteria were transferred after 48 h into Brucella broth
containing 5% fetal bovine serum for 24 h. A multipli-
city of infection of 100 was used in all studies.
Real-time reverse-transcription PCR
Total RNA was isolated from tissues and cell lines by
Trizol (Takara, Dalian, China) according to the proto-
col supplied by the manufacturers. cDNA was synthe-
sized using Takara RNA PCR 3.0 Kit (Takara, Dalian,
China) in a total volume of 10 μl, containing AMV
reverse transcriptase, 0.5 μl; random 9 primer, 0.5 μl;
25 mM MgCL2,2μl; 10 × RT Buffer, 1 μl; dNTP mix-
ture (each 10 mM), 1 μl; RNase inhibitor, 0.25 μl;
RNA 1 μl; dH2O, 3.75 μl. Conditions for RT were:
30°C for 10 minutes, 42°C for 25 minutes, 99°C for
5 minutes, and 5°C for 5 minutes. Real-time PCR was
performed using the LightCycler system together with
the LightCycler DNA Master SYBR Green I Kit (Roche
Diagnostics). The total volume is 20 μl, containing
25 mM MgCl2,3μl; 10 × Buffer, 5 μl; 10 μMf o r w a r d
Primer, 1 μl; 10 μM reverse Primer, 1 μl; LightCycler
DNA Master SYBR Green I, 2 μl; cDNA, 2 μl; dH2O,
6 μl. Conditions for PCR were: 50°C for 2 minutes,
95°C for 10 minutes, and then 40 cycles of 5 seconds
at 95°C and 20 seconds at 60°C. The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control. Gene
expression was quantified by the comparative CT
method, normalizing CT values to GAPDH and calcu-
lating relative expression values. Primer sequences
were provided by Takala (Dalian, China) as follows:
CXCR4 forward, 5′-GAGGAAATGGGCTCAGGG-3′,
reverse, 5′-AGTCAGCAGGAGGGCAGGGA-3′; TNF-a
forward, 5′-AG TGACAAGCCTGTAGCCC-3′, reverse,
5′-GCAATGATCCCAAAGTAGACC-3′; IL-1b forward,
5′-CCACCACTACAGCAAGGG-3′,r e v e r s e ,5 ′-GAACT
GGGCAGACTCAAA-3′; IL-6 forward, 5′-CCTTCGGT
CCAGTTGCCTTCT-3′,r e v e r s e ,5 ′-GCATTTGTG




Cell lysates were prepared with sample buffer [50 mmol/
L Tris-HCl (pH 6.8), 100 mmol/L DTT, 2% SDS, 0.1%
bromophenol blue, and 10% glycerol] and were sub-
jected to a 12% sodium dodecyl sulfate (SDS)/acrylamide
gel. The proteins on acrylamide gel were transferred to a
nylon membrane, which was blocked overnight (4°C in
PBS with 0.1% Tween and 10% milk powder). Polyclonal
antibodies for CXCR4 (Santa Cruz, CA, America), and
the corresponding secondary antibodies (Santa Cruz,
CA, America) were applied before immunoblotting. The
human gene b-actin (Santa Cruz, CA, America) was
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FX pro plus system (Bio-Rad) and quantified using
Scion Image 4.03 software.
RNA interference
TNF-a RNAi plasmid and nonsilencing control RNAi
plasmid were purchased from Takala (Dalian, China).
Cells were seeded into a 24-well plate at a density of
2×1 0
5 . On the following day, cells were transfected
with TNF-a siRNA or Control siRNA using Lipofecta-
mine 2000 (Invitrogen, United Kingdom) according to
the manufacturer’s instructions.
Elisa for cytokines in cell culture supernatants
Concentrations of TNF-a, IL-1b and IL-6 in cell culture
supernatants were measured using the Quantikine Elisa
kit (Boster, Wuhan, China) according to the manufac-
turer’s instructions. The sensitivity of the assay was
2p g / m lf o rT N F - a,4p g / m lf o rI L - 1 b and 4 pg/ml
for IL-6.
Migration assays
The migration of cultured cells was assayed using Matri-
gel invasion chamber (24-well format, 8 μmp o r e ;B D
pharmingen). Cells (5 × 10
5 ) were added to the upper
chamber and medium supplemented with CXCL12 (100
ng/ml, Sigma) was added to the lower chamber. Migra-
tion assays were incubated for 18 hours at 37°C and 5%
CO2. Migrated cells on the lower surface were stained
using 1% toluidine blue after fixation with 100% metha-
nol. For each transwell, the number of migrated cells in
10 medium power fields (× 20) was counted.
Statistical analysis
Mann-Whitney U-test was used to compare mRNA
expression between H. pylori-positive and H. pylori-
negative tumors. Correlation between CXCR4 expres-
sion and TNF-a expression in gastric cancer specimens
was analyzed using Spearman’s rank correlation test.
Expression of mRNA in gastric cell lines was compared
using Student’s t-test or one way ANOVA. Statistical
analysis was carried out using SPSS version 11.0 (SPSS,
Chicago, IL, USA). Difference was considered significant
when P-value was < 0.05.
Results
Expression of CXCR4 and TNF-a mRNA in primary gastric
cancers
CXCR4 mRNA was determined by real-time reverse-
transcription PCR in 34 gastric cancers, and its expres-
sion in each specimen was standardized to GAPDH
expression. The results revealed its level significantly
higher in H. pylori-positive gastric cancers (n = 19)
compared to H. pylori-negative ones (n = 15) (7.2 fold,
P < 0.01, Figure 1A). In the same cohort of tumors,
TNF-a mRNA expression was also detected by real-
time reverse-transcription PCR, and it was found stron-
ger in H. pylori-positive gastric cancers compared to H.
pylori-negative ones (4.3 fold, P < 0.01, Figure 1B).
Spearman’s rank correlation test further verified a posi-
tive correlation of CXCR4 expression with TNF-a in
these 34 gastric cancers (P < 0.01, Figure 1C).
Induction of CXCR4 and TNF-a expression by H. pylori in
gastric cancer cells
Real time-PCR and Western blotting were used to
detect CXCR4 expression in MKN45 and HGC27 cells
(Figure 2A, B); and reveal it upregulated significantly in
them after infection with H. pylori 26695 for 24 hours
(P < 0.01, respectively, Figure 2A, B). Subsequently they
were treated with a cag PAI-negative H. pylori, Tx30a to
determine its involvement in the upregulation, and it is
also found to induce CXCR4 expression in MKN45 and
HGC27 cells (P < 0.01, respectively, Figure 2A, B).
The effect of H. pylori infection on TNF-a expression
was further investigated using real-time PCR and Elisa,
and the detection revealed that infection with 26695 or
Tx30a for 12 hours may have led to both more expres-
sion of TNF-a mRNA (P < 0.01, respectively) and more
secretion of TNF-a protein into the culture supernatant
(P < 0.01, respectively) in MKN45 and HGC27 cells
(Figure 2C, D).
Effect of Infliximab, a neutralizing antibody to TNF-a,o n
the induction of CXCR4 expression by H. Pylori
The finding of upregulation of TNF-a expression in this
case brought us to further research on its involvement
in the induction of CXCR4 expression by H. pylori. A
neutralizing TNF-a antibody, infliximab (4 μg/ml,
Sigma), was then used to treat MKN45 and HGC27
cells after an infection by 26695, and the induction of
CXCR4 was inhibited significantly (P <0 . 0 1 ,r e s p e c -
tively, Figure 3A, B). Similar results were observed when
these cells were treated with infliximab after an infection
by Tx30a (P < 0.01, respectively, Figure3C, D).
Upregulation of CXCR4 expression in gastric cancer cells
by TNF-a
MKN45 cells, which secret lower level of TNF-a pro-
tein, were treated with 1, 10, or 50 ng/ml TNF-a
(Sigma) for 6 hours in attempt to further explore the
role of TNF-a in the upregulation of CXCR4 expression,
and real time-PCR and Western blotting detection
revealed it was upregulated significantly in a dose-
dependent manner (P < 0.01, Figure 4A, B), and even by
15.8 folds with 50 ng/ml TNF-a treatment.
Next, the CXCR4 expression within a co-culture sys-
tem was examined, since tumor-associated macrophages
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Page 3 of 10Figure 1 Expression of CXCR4 and TNF-a mRNA in primary gastric cancers by real-time PCR. (A) and (B) H. pylori-positive gastric cancers
(grey columns, n = 19) expressed higher level of CXCR4 (A) and TNF-a (B) mRNA compared to H. pylori-negative gastric cancers (black columns,
n = 15), *P < 0.01. Horizontal lines: means of mRNA level. (C) Level of CXCR4 mRNA was correlated positively with that of TNF-a mRNA in 34
gastric cancers, P < 0.01. Black rhombus: H. pylori-negative gastric cancers; grey rhombus: H. pylori-positive gastric cancers.
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microenvironment. A co-culture of MKN45 cells with
RAW264.7 cells for 24 hours indicated it expressed sig-
nificantly more CXCR4 mRNA and protein (P < 0.001,
Figure 4C, D); this increase, however, was significantly
inhibited by infliximab (P < 0.001, Figure 4C, D).
Finally, endogenous TNF-a was targeted to evaluate
its regulation on CXCR4 expression in HGC27 cells,
which secrets higher level of TNF-a protein. TNF-a
RNAi plasmid was used to transfect HGC27 cells, and
correspondingly nonsilencing RNAi plasmid was
employed in the counterpart as control. It was observed
that expression of TNF-a was absent in HGC27 cells
after transfection with TNF-a RNAi plasmid (Figure
4E). Then expression of CXCR4 was detected by real-
time PCR, and it was noted in the detection that, after
transfection with TNF-a RNAi plasmid, CXCR4 mRNA
expression was downregulated significantly in HGC27
cells, compared with cells with control RNAi or cells
without RNAi (P < 0.001, respectively, Figure 4F).
Induction of cytokines in macrophages by H. Pylori
Real-time PCR and Elisa were employed to evaluate the
effect of H. pylori 26695 on cytokine expression in
RAW264.7 cells, since it is generally acknowledged that
cytokines are involved in chronic inflammatory pro-
cesses caused by H. Pylori. The real-time PCR detection
showed expression of TNF-a,I L - 1 b and IL-6 mRNA
was upregulated in 26695-treated cells compared to
26695-untreated cells (TNF-a, P < 0.001; IL-1b, P <
0.001 and IL-6, P <0 . 0 0 1 ,F i g u r e5 A ) .A n dE l i s ar e s u l t s
indicated more proteins of TNF-a,I L - 1 b and IL-6 were
secreted into culture supernatant in 26695-treated cells
compared to 26695-untreated cells (TNF-a, P < 0.001;
IL-1b, P < 0.001 and IL-6, P < 0.001, Figure 5B).
Finally MKN45 cells were treated with exogenous IL-
1b (50 ng/ml) and IL-6 (50 ng/ml) respectively, to rule
out the possibility that IL-1b and IL-6 may upregulate
CXCR4 expression like TNF-a.N e i t h e rI L - 1 b nor IL-6
was found to upregulate CXCR4 expression significantly
(Figure 5C, D).
Migration analysis
Migration analysis was performed using the Matrigel
invasion chamber in an attempt to investigate whether
the upregulated CXCR4 was functional. In the initial
phase of the experiment with 100 ng/ml of CXCL12 in
the lower chamber, there was a significant increase (up
to 4.5 folds) in the migration of MKN45 cells with
26695 treatment in the upper chamber, compared with
Figure 2 Expression of CXCR4 and TNF-a in MKN45 and HGC27 cells after infection with H. pylori. (A) and (B) CXCR4 expression was
upregulated in MKN45 and HGC27 cells after infection with H. pylori 26695 (*P < 0.01, respectively, vs H. pylori
- ) or Tx30a (*P < 0.01,
respectively, vs H. pylori
- ). (C) and (D) TNF-a expression was increased in MKN45 and HGC27 cells after infection with H. pylori 26695 (*P < 0.01,
respectively, vs H. pylori
- ) or Tx30a (*P < 0.01, respectively, vs H. pylori
- ). Data are expressed as mean ± SD, n = 3.
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6A). Later on, however, the increase was inhibited
remarkably when AMD 3100 (1 μg/ml, Sigma), a
CXCR4 antagonist, or infliximab, was added (P < 0.01,
respectively, Figure 6A).
In addition, the effect of cytokines on MKN45 cell
migration was also examined, and TNF-a (50 ng/ml)
was found to increase MKN45 cell migration signifi-
cantly (P < 0.001, Figure 6B). However, neither IL-1b
(50 ng/ml) nor IL-6 (50 ng/ml) was proved to promote
MKN45 cell migration considerably (Figure 6B).
Discussion
H. pylori is blamed to infect about 50% of the world’s
population as a definitive gastric carcinogen for humans
[12]. Pathogenesis of its infection often includes inflam-
mation, mucosal damage, or gastric atrophy, and
requires close interactions between the bacteria and the
gastric epithelial cells, activating signalling pathways,
modifying host cellular functions, and leading to chronic
epithelial responses [13.14]. There are now considerable
evidences linking chronic inflammation to human can-
cers [15-17], and specifically, H. pylori-induced chronic
inflammation and cytokines in local stomach microen-
vironment serve as the most common contributors
[18-20]. This study highlights the result that mucosal
level of TNF-a mRNA was significantly higher in H.
pylori positive patients than that in negative patients by
using quantitative real-time PCR, and two gastric cancer
cells also secreted TNF-a protein in vitro. It further
points to the assumption that TNF-a m a yb ei n v o l v e d
in H. pylori positive gastric carcinogenesis as an indis-
pensable and strong linker between inflammation and
cancer [21].
Though the mechanism of induction of TNF-a by H.
pylori remains relatively unclear, a protein family has
been disclosed in the last decade, including Helicobacter
pylori-membrane protein-1 (HP-MP1) and TNF-a indu-
cing protein (Tipa) [22-24]. Tipa gene, identified from
H. pylori strain 26695, is homologous to HP-MP1 gene
with 94.3% homology, and both of them show strong
ability to induce TNF-a gene expression. In the study,
H. pylori 26695 was found to upregulate TNF-a expres-
sion significantly in MKN45 and HGC27 cells, and cag
PAI negative strain Tx30a also was spotted to induce it
obviously, which may be in part due to the fact that
HP-MP1/Tipa family is not in cag PAI region. However,
it was also noted that the effect of Tx30a on TNF-a
induction was weaker than that of 26695 (2.3 folds vs
3.1 folds in MKN45 cells), which suggested H. pylori
Figure 3 Effect of infliximab on the induction of CXCR4 expression by H. Pylori.( A )a n d( B )C X C R 4u p r e g u l a t i o ni n d u c e db yH .p y l o r i
26695 was inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P < 0.01, respectively, vs 26695 + inf. (C) and (D) CXCR4
upregulation induced by H. pylori Tx30a was also inhibited in MKN45 and HGC27 cells after treatment with infliximab, *P < 0.01, respectively, vs
Tx30a + inf. Data are expressed as mean ± SD, n = 3. inf: infliximab.
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tion. In fact, it had been reported that cagA of H. pylori
could induce TNF-a in gastric cancer biopsy specimens
[25]. In addition, purified H. pylori urease was also
found to induce MKN45 cells to express TNF-a [26].
TNF-a, a key cytokine in many chronic inflammatory
diseases, was originally labelled as a serum factor for the
induction of hemorrhagic necrosis of transplanted solid
tumors in mice. However, presently it is commonly
identified as a tumor promoter in local tumor microen-
vironment, and therefore the deletion or inhibition of it
is supposed to reduce the incidence of experimental
cancers. TNF-a/TNF-R1 knock down mice are resistant
to chemical-induced carcinogenesis [27,28]. It is
frequently detected in biopsies from a variety of human
cancers, produced either by epithelial tumor cells or
stromal cells. Additionally, it is also found, though in
low amount, in the secretion of many cancer lines in
vitro without inflammatory stimuli, though the mechan-
ism is still not completely clear.
TNF-a was found not only involved in cell transfor-
mation and proliferation, but also in tumor metastasis.
Such a finding was initially based on an animal model
with colon cancer, in which injection of LPS enhanced
the development of lung metastasis dependent on TNF-
a production by host cells [29]. The subsequent results
showed the increased tumor metastasis inhibited by
neutralizing TNF-a antibody [30]. These led to our
Figure 4 Upregulation of CXCR4 expression in gastric cancer cells by TNF-a. (A) and (B) CXCR4 expression was upregulated in MKN45 cells
by exogenous TNF-a in a dose-dependent manner, *P < 0.01. (C) and (D) The coculture system of MKN45 and RAW264.7 cells expressed more
CXCR4, *P < 0.001, vs M; **P < 0.001, vs R. The upregulation of CXCR4 expression was inhibited after treatment with infliximab, ***P < 0.001, vs M
+ R + inf. M: MKN45; R: RAW264.7; inf: infliximab. (E) Expression of TNF-a was absent in HGC27 cells after transfection with TNF-a RNAi plasmid.
(F) CXCR4 mRNA expression was downregulated in HGC27 cells after transfection with TNF-a RNAi plamid, *P < 0.001, vs No RNAi; **P < 0.001,
vs Control RNAi. Data are expressed as mean ± SD, n = 3.
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TNF-a in tumor metastasis may be related to the upre-
gulation of chemokines/chemokine receptors. First,
there was a significant upregulation of CXCR4 in gastric
cancer cells after they were treated with exogenous
TNF-a. There was another obvious upregulation of
CXCR4 expression in cancer cells after they were co-
cultured with macrophage, an alternative source of
TNF-a in gastric cancer microenvironment. As was
expected, this upregulation could be inhibited by TNF-a
neutralizing antibody infliximab. There was conse-
quently a remarkable reduction of the expression of
CXCR4 in HGC27 cells after RNAi was employed to
abrogate the TNF-a expression in these cells, which
indicated endogenous TNF-a can also upregulate
CXCR4 expression. The overall findings led to our con-
clusion that TNF-a, with itself involved in the metasta-
sis of gastric cancer, upregulates CXCR4 expression.
Overexpression of CXCR4, whose involvement in var-
ious human tumors is well known, was frequently
observed in gastric cancer tissues to increase gastric
cancer metastasis. Some human gastric carcinoma cells
also express CXCR4 mRNA and protein at high levels
[7,8]. Our study showed H. pylori infection increased
MKN45 cell migration through the upregulation
of CXCR4 expression. The treatment with a CXCR4
antagonist AMD3100 resulted in a significant
suppression of MKN45 cell mig r a t i o ni nv i t r o .A n o t h e r
study showed AMD3100 significantly suppressed the
development of peritoneal carcinomatosis in a mouse
model of gastric cancer, which was evidenced by the
reduction of tumor growth and ascitic fluid formation
[9]. The previous researches led to our conclusion that
CXCR4 overexpression in biopsy specimen of primary
gastric cancer may serve as a preoperative evaluation of
risks for the occurrence of peritoneal carcinomatosis.
Macrophages’ involvement in the carcinogenesis and
tumor invasion and metastasis [31,32] generally is
blamed to motivate TAMs (Tumor associated macro-
phages), a major source of TNF-a in tumor microenvir-
onment, to release a variety of growth factors, cytokines,
and inflammatory mediators. The study revealed there
was a significant expression of TNF-a induced by H.
pylori, and simultaneously upregulation of IL-1beta and
IL-6 in RAW264.7 cells, However, the latter variation
failed to induce CXCR4 expression in MKN45 cells.
Studies have ultimately attributed the abnormal activa-
tion of NF-B in cancer cells to the excessive secretion
of TNF-a, whose role in CXCR4 upregulation is subse-
quently assumed to be related to pathways mediated by
NF-B. Others findings have revealed TNF-a antago-
nists can inhibit the upregulation of CXCR4 expression
by H. pylori, and both it and CXCR4 antagonists can
suppress the increased migration of gastric cancer cells
Figure 5 Induction of cytokines in macrophages by H. Pylori. (A) and (B) Expression of TNF-a,I L - 1 b and IL-6 was upregulated in 26695-
treated RAW264.7 cells, *P < 0.001, vs untreated cells. (C) and (D) Neither IL-1b nor IL-6 can upregulate CXCR4 expression in MKN45 cells. Data
are expressed as mean ± SD, n = 3.
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alone, or in combination with other therapies, may serve
as effective therapies for gastric cancer patients.
Conclusions
TNF-a is involved in the upregulation of CXCR4
expression in gastric cancer induced by H. pylori.
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